RS53104A - Chemically-modified human growth hormone conjugates - Google Patents

Chemically-modified human growth hormone conjugates

Info

Publication number
RS53104A
RS53104A YU53104A YUP53104A RS53104A RS 53104 A RS53104 A RS 53104A YU 53104 A YU53104 A YU 53104A YU P53104 A YUP53104 A YU P53104A RS 53104 A RS53104 A RS 53104A
Authority
RS
Serbia
Prior art keywords
chemically
growth hormone
human growth
modified human
hgh
Prior art date
Application number
YU53104A
Other languages
Serbian (sr)
Inventor
Rory F. Finn
Wei Liao
Ned R. Siegel
Original Assignee
Pharmacia Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corporation filed Critical Pharmacia Corporation
Publication of RS53104A publication Critical patent/RS53104A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Abstract

The present invention provides a chemically modified human Growth Hormone (hGH) prepared by binding a water soluble polymer to the protein. The chemically-modified protein according to the present invention may have a much longer lasting hGH activity than that of the unmodified hGH, enabling reduced dose and scheduling opportunities.
YU53104A 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates RS53104A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20
PCT/US2002/037270 WO2003044056A2 (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Publications (1)

Publication Number Publication Date
RS53104A true RS53104A (en) 2006-10-27

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
YU53104A RS53104A (en) 2001-11-20 2002-11-20 Chemically-modified human growth hormone conjugates

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20050044858A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA200700431A1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
AU2002357806A1 (en) * 2001-12-11 2003-06-23 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
MEP35608A (en) * 2002-01-18 2011-02-10 Biogen Idec Inc Polyalkylene polymer compounds and uses thereof
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
KR100974843B1 (en) 2002-09-09 2010-08-11 넥타르 테라퓨틱스 Water-soluble polymer alkanals
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
ES2349743T3 (en) * 2003-10-10 2011-01-11 Novo Nordisk A/S DERIVATIVES OF IL-21.
CN1909930B (en) * 2004-01-21 2015-12-16 诺和诺德医疗保健公司 The joint of transglutaminase mediated peptide
KR20070042567A (en) * 2004-08-31 2007-04-23 파마시아 앤드 업존 캄파니 엘엘씨 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
JP5425398B2 (en) * 2004-12-22 2014-02-26 アンブレツクス・インコーポレイテツド Compositions comprising unnatural amino acids and polypeptides, methods relating to unnatural amino acids and polypeptides, and uses of unnatural amino acids and polypeptides
EP1836314B1 (en) * 2004-12-22 2012-01-25 Ambrx, Inc. Modified human growth hormone
NZ555206A (en) * 2004-12-22 2010-09-30 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
EP2360181B1 (en) 2005-04-18 2013-09-18 Novo Nordisk A/S IL-21 variants
CN101268098A (en) 2005-08-30 2008-09-17 诺沃-诺迪斯克保健股份有限公司 Liquid formulations of pegylated growth hormone
JP5508716B2 (en) * 2005-11-08 2014-06-04 アンブルックス，インコーポレイテッド Accelerators for modifying unnatural amino acids and unnatural amino acid polypeptides
CA2882445A1 (en) 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2655188A1 (en) * 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
CA2666426A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
US9840546B2 (en) 2008-04-03 2017-12-12 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human growth hormone derivative linked with polyethyleneglycol, method for the preparation thereof and pharmaceutical composition comprising the same
CN102131844B (en) * 2008-07-31 2016-03-02 药华医药股份有限公司 Peptide-polymer conjugates
CN102112157B (en) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 Conjugated proteins with prolonged in vivo efficacy
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
EP2331139B1 (en) * 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
JP5816097B2 (en) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
SG181648A1 (en) 2009-12-15 2012-07-30 Ascendis Pharma As Dry growth hormone composition transiently linked to a polymer carrier
JP5980689B2 (en) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
SI2525834T1 (en) 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Growth hormones with prolonged in-vivo efficacy
JP2013533217A (en) * 2010-05-17 2013-08-22 セビックス・インコーポレイテッド PEGylated C-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
KR20230079520A (en) 2014-11-06 2023-06-07 파마에센시아 코퍼레이션 Dosage Regimen for PEGylated Interferon
MX2017011562A (en) * 2015-03-11 2018-05-11 Nektar Therapeutics Conjugates of an il-7 moiety and an polymer.
US10842879B2 (en) 2015-09-18 2020-11-24 University Of Miyazaki Long-acting adrenomedullin derivative
CN114539384A (en) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, and preparation method and medical application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE69128944T2 (en) * 1990-05-04 1998-06-25 American Cyanamid Co Stabilization of somatotropin through modification of cysteine residues
JPH06506217A (en) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0851925B1 (en) * 1995-09-21 2005-08-03 Genentech, Inc. Human growth hormone variants
EP1881005B1 (en) * 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
ATE526401T1 (en) * 1999-01-14 2011-10-15 Bolder Biotechnology Inc METHOD FOR PRODUCING PROTEINS WITH FREE CYSTEINE RESIDUE
PT1157037E (en) * 1999-01-29 2003-12-31 Hoffmann La Roche GCSF CONJUGATES
WO2001076639A2 (en) * 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
JP2004524020A (en) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス Improved growth hormone molecule

Also Published As

Publication number Publication date
JP2005525302A (en) 2005-08-25
EA200400565A1 (en) 2005-06-30
HUP0500997A2 (en) 2007-11-28
PL374354A1 (en) 2005-10-17
EA008505B1 (en) 2007-06-29
ECSP045114A (en) 2004-07-23
BR0214451A (en) 2006-05-30
MXPA04004809A (en) 2004-08-11
EA200700431A1 (en) 2008-02-28
KR20050044858A (en) 2005-05-13
CN1608079A (en) 2005-04-20
OA13063A (en) 2006-11-10
NO20042182L (en) 2004-08-11
CA2467731A1 (en) 2003-05-30
JP2006321808A (en) 2006-11-30
ZA200403907B (en) 2007-12-27
WO2003044056A3 (en) 2003-08-21
IS7268A (en) 2004-05-17
HRP20040448A2 (en) 2006-02-28
KR20070072924A (en) 2007-07-06
AP2004003050A0 (en) 2004-06-30
CO5580794A2 (en) 2005-11-30
EP1453859A2 (en) 2004-09-08
MA27544A1 (en) 2005-10-03
GEP20063860B (en) 2006-06-26
IL162031A0 (en) 2005-11-20
AU2002356990A1 (en) 2003-06-10
TNSN04090A1 (en) 2006-06-01
WO2003044056A2 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
MXPA04004809A (en) Chemically-modified human growth hormone conjugates.
MXPA05004993A (en) Chemically-modified human growth hormone conjugates.
DK1715887T3 (en) N-terminal Monopegylated Human Growth Hormone Conjugates, Methods for their Preparation and Use
MX344559B (en) Pegylated recombinant human growth hormone compounds.
WO2002057293A3 (en) Modified zinc finger binding proteins
WO2006033859A3 (en) Compositions and methods for protein production
BG108499A (en) A novel engineered superantigen for human therapy
GB2436265A (en) Formulations of human growth hormone comprising a non-naturally encoded amino acid
AU2003303598A1 (en) Compositions, methods, and systems for inferring bovine breed
AU3441400A (en) Peptide
WO2001076639A3 (en) Chemically-modified myelopoietin conjugates
MXPA04000068A (en) Chemically-modified progenipoietin conjugates.
MXPA04002103A (en) A caspase- 8 binding protein, its preparation and use.
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
WO2002099438A3 (en) Modulation of steroid hormone uptake
HK1082510A1 (en) Promoter to il-18bp, its preparation and use
PL363501A1 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same
WO2003099863A3 (en) Resistin binding proteins, their preparation and use
EP1437364A3 (en) Polypeptide binding to the androgen receptor and its potential use for treating breast cancer
WO2002062996A1 (en) Novel physiologically active peptide and use thereof
TW200635950A (en) Specific binding agents of human angiopoietin-2